Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2026-04-27 Declaration of Voting R…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal regulatory announcement disclosing the total number of shares and voting rights as required under article L. 233-8 II of the French Commercial Code and AMF regulation article 223-16. It is not an earnings release, annual report, management change, or share issue. It specifically relates to voting rights disclosure, fitting the category "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2026-04-27 French
ABIVAX: Nombre dactions composant le capital social et nombre total de droits de vote
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement (under 5,000 characters) providing the total number of shares and voting rights for ABIVAX in accordance with French AMF requirements. It is neither a financial report (10‐K/IR), management or board change, dividend notice, nor a detailed investor presentation. It does not report an M&A, share issue, buyback, or insider transaction. It is a generic regulatory filing to satisfy disclosure obligations. Therefore, it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-27 French
Abivax présentera des données sur l’obefazimod lors de la Digestive Disease Week
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that Abivax will present clinical data at the Digestive Disease Week conference. It does not contain financial results or a detailed investor slide deck; it is not an earnings release, dividend notice, management change, or regulatory report. It is a general investor relations announcement (press release) that does not fit any other specific category, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-22 French
Abivax presentera des donnees sur lobefazimod lors de la Digestive Disease Week
Regulatory Filings Classification · 1% confidence The document is a regulatory press release notifying the market that Abivax will present clinical data at the Digestive Disease Week conference. It does not contain financial results, voting outcomes, board changes, or formal regulatory report content. It is a general corporate announcement published via EQS, fitting the catch‐all Regulatory Filings category (RNS).
2026-04-22 French
Abivax assemblée générale ordinaire annuelle et extraordinaire du 11 mai 2026 - Mise à disposition des documents préparatoires
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a notice to shareholders of the upcoming annual and extraordinary general meeting (AGM) on May 11, 2026, providing the meeting agenda, draft resolutions, and details on how to access preparatory materials per legal requirements. This corresponds to materials sent to shareholders to solicit proxies and provide information for voting, matching the Proxy Solicitation & Information Statement (PSI) category.
2026-04-20 French
Abivax assemblee generale ordinaire annuelle et extraordinaire du 11 mai 2026 - Mise a disposition des documents preparatoires
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an announcement that preparatory materials (agenda, resolutions, participation modalities) for the upcoming Annual General Meeting are now available to shareholders. These are the typical proxy solicitation and information statement materials sent out or made available ahead of an AGM to inform and allow voting. Therefore, it best fits the Proxy Solicitation & Information Statement category (PSI).
2026-04-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.